Home
/
Aclaris Therapeutics, Inc.
/
Financials
/
Quarterly
Aclaris Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aclaris Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$1.12M
May 8, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$3.30M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$1.78M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$1.46M
May 8, 2025
Q3
2025
Sep 30, 2024
$4.35M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$2.77M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$2.40M
May 8, 2025
Q3
2024
Sep 30, 2023
$9.28M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$1.87M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$2.53M
May 7, 2024
Q3
2023
Sep 30, 2022
$19.02M
Nov 6, 2023
Q2
2023
Jun 30, 2022
$1.53M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$1.45M
May 8, 2023
Q3
2022
Sep 30, 2021
$1.66M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$1.82M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$1.78M
May 10, 2022
Q3
2021
Sep 30, 2020
$1.45M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$2.05M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$1.41M
May 7, 2021
Q3
2020
Sep 30, 2019
$983.0K
Nov 4, 2020
Q2
2020
Jun 30, 2019
$886.0K
Aug 7, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$684.0K
Nov 7, 2017
Q3
2015
Sep 30, 2015
$0
Dec 3, 2015
Q3
2015
Sep 30, 2014
$0
Dec 3, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($14.61M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($15.43M)
Aug 7, 2025
Q3
2025
Jun 30, 2025
($15.43M)
Nov 6, 2025
Q3
2025
Mar 31, 2025
($15.09M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($15.09M)
May 8, 2025
Q2
2025
Mar 31, 2025
($15.09M)
Aug 7, 2025
Q3
2025
Sep 30, 2024
($7.59M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($10.99M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($10.99M)
Nov 6, 2025
Q2
2025
Mar 31, 2024
($16.94M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($16.94M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($16.94M)
May 8, 2025
Q3
2024
Sep 30, 2023
($29.26M)
Nov 6, 2024
Q3
2024
Jun 30, 2023
($29.57M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($29.57M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($28.16M)
May 7, 2024
Q2
2024
Mar 31, 2023
($28.16M)
Aug 7, 2024
Q3
2024
Mar 31, 2023
($28.16M)
Nov 6, 2024
Q3
2023
Sep 30, 2022
($19.95M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($20.53M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($17.15M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($18.41M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($18.08M)
May 8, 2025
Q3
2025
Sep 30, 2024
($10.47M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($12.85M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($18.93M)
May 8, 2025
Q3
2024
Sep 30, 2023
($31.58M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($31.82M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($29.92M)
May 7, 2024
Q3
2023
Sep 30, 2022
($20.87M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($20.99M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($18.91M)
May 8, 2023
Q3
2022
Sep 30, 2021
($20.30M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($18.01M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($28.53M)
May 10, 2022
Q3
2021
Sep 30, 2020
($10.47M)
Nov 2, 2021
Q2
2021
Jun 30, 2020
($11.38M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($15.51M)
May 7, 2021
Q3
2020
Sep 30, 2019
($22.86M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($43.60M)
Aug 7, 2020